ProofPilot Bolsters Advisory Board with Appointment of Michelle Everill
Michelle has over 20 years of diverse experience spanning across data analytics, clinical operations, patient recruitment and feasibility strategy. She has held leadership roles at Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, Pfizer and PPD.
"Michelle adds a tremendous amount of knowledge and fresh perspectives to our team," said
As a member of the Strategic Advisory Board, Michelle will provide invaluable guidance on product direction and strategic initiatives to improve the patient, site, and study team experience in clinical trials.
"Joining ProofPilot's Strategic Advisory Board is an exciting opportunity to work with a forward-thinking team dedicated to modernizing clinical trials," said Michelle Everill, VP, Global Trial Optimization at Alnylam Pharmaceuticals, and CEO of Michelle Everill Coaching LLC. "I am eager to contribute my expertise to initiatives that will drive impactful advancements in clinical research, leveraging innovative strategies to improve trial outcomes and patient experiences."
ProofPilot will continue to announce new members of its Strategic Advisory Board, ensuring its solutions deliver immediate and long-term value for all stakeholders.
About ProofPilot
ProofPilot enhances clinical trials with its Clinical Experience Platform. The StudyCoPilot platform centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. Learn more at: https://www.proofpilot.com.
Media Contact: Colleen yang, [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/proofpilot-bolsters-advisory-board-with-appointment-of-michelle-everill-302236917.html
SOURCE ProofPilot
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Come Back to Firefox: Mozilla launches its most ambitious campaign yet to bring people back to the independent alternative to big tech browsers
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
- TRON Price Prediction: $23M Revenue Report Beats ETH and SOL Combined as Remittix Plans 41 More Fiat Currencies
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share